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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not curcumin,
whether alone or in conjunction with alternative therapy, has an effect on Major Depressive
Disorder (MDD).
Study Design: Systematic review of 3 primary studies, published between 2013 and 2016.
Data Sources: Three randomized control trials (RCT), two of which were double blind. These
studies were found using Cochrane Systematic Reviews and PubMed.
Outcomes Measured: Outcome for all three articles are symptomatic changes of MDD. The
outcomes measured were Patient-Oriented Evidence that Matters (POEMS) and were assessed
using various self-rated tools.
Results: All three studies demonstrated an improvement in depressive symptoms compared to
placebo or other control groups. In Lopresti, Maes et al., curcumin has a significant effect on
symptoms compared to placebo (p=0.045).1 In Sanmukhani et al., an improvement was seen in
the group receiving curcumin, although not statistically significant (p=0.58).2 Lastly, Lopresti,
Drummond compared placebo to low-dose curcumin, high-dose curcumin, and low-dose
curcumin combined with saffron. In this study, drug treatment with curcumin had a positive
effect on patients with depression (p=0.012), although there was no difference between the
differing curcumin doses or curcumin/saffron combination.3
Conclusions: Curcumin does appear to be safe and effective for adults suffering from MDD.
Two out of the three trials included in this systematic review were able to show significant data
in support of the positive effects of curcumin. The use of curcumin for symptomatic relief in
MDD is promising, however, more RCT must be done to support this.
Keywords: curcumin, depression, major depressive disorder
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INTRODUCTION
Major depressive disorder is a mental health condition that is characterized by chronic
depressed mood and/or loss of interest in activities and hobbies. Oftentimes, there may be
accompanying low self-esteem, decreased energy, fatigue, and non-specific pain. It was initially
thought that a disturbance is in the level of serotonin was the major cause of MDD, however, it is
now known that there are many other dysregulations that contribute, such as, dysregulation in the
hypothalamic-pituitary-adrenal axis, activation of immune-inflammatory pathways,
mitochondrial dysfunction, and neuroprogression.1
MDD affects individuals worldwide and is a cause of impaired functional capacity which can
lead to suicides.2 It affects approximately 6-8 percent of adults each year with a lifetime
prevalence of 15-20%.3 Because MDD is only a small aspect of mental health disorders, there is
not an exact number of yearly healthcare visits. However, according to the CDC, the percent of
physician office visits with depression indicated on the medical record is 10.4%, It is estimated
that a total of $210.5 billion are spent per year for MDD patients. 4, 5
There are several traditional methods that are used to treat MDD. Specific prescription
medications include, selective serotonin reuptake inhibitors (SSRIs), serotonin and
norepinephrine reuptake inhibitors (SNRIs), dopamine reuptake blockers, and tricyclic
antidepressants. Cognitive behavioral therapy and electroconvulsive therapy is sometimes used
in conjunction. Because the disease is chronic, patients must be on long term treatment, however,
pharmacological therapy has significant adverse reactions and side effects. Additionally, some
patients may be resistant to these medications. Therefore, a safer alternative is being searched
for.2 Curcumin is the major active ingredient in turmeric (Curcuma longa), which often used as a
southeast Asian cooking spice. It is a potent antioxidant that can lower markers of antioxidant
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stress, act as a COX-2 inhibitor, and lower pro-inflammatory cytokines.1 Additionally, it can
affect the hypothalamic-pituitary-adrenal axis and influence monoamine transmission through its
effects on serotonergic and dopaminergic activity.1

OBJECTIVE
The objective of this selective EBM review is to determine “what are the effects of
curcumin, whether alone or in conjunction with alternative therapy, on major depressive
disorder?”

METHODS
This selective EBM review analyzed 3 randomized control studies that evaluated the
aforementioned objective. The population criteria included males and females over the age of 18
who are suffering from MDD. All three RTCs used curcumin as the main intervention compared
to placebo or another control group. Two of the three trials (Lopresti, Drummond and
Sanmukhani et al.) had multiple arms in their studies and further evaluated the combination of
curcumin with other therapy options. The outcomes measured in all three RTCs were
symptomatic changes of MDD using various self-rating tools such as, Inventory of Depressive
Symptomatology self-rated score (IDS-SR30 score), Spielberger State-Trait Anxiety Inventory
tool (STAI tool), and Hamilton Depression Rating Scale (HAM-D17 scale).
Keywords used to search for the articles included, “curcumin”, “depression”, and “major
depressive disorder”. All articles were found on PubMed and published in the English language.
Types of studies searched included only RTCs that were POEMs, included human species data,
and originally published in a peer reviewed journal within the last 10 years. Any studies that
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were found on the Cochrane database or previously published by a student were excluded. Other
exclusion criteria included patients not suffering from MDD or were being evaluated for MDD
and another concurrent disease. Summary of statistics used were relative risk reduction (RRR),
absolute benefit increase (ABI), numbers needed to treat (NNT), p-value, and ANOVA F-score.
The demographics and characteristics of the individuals included in these studies are displayed in
Table 1.
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Table 1: Demographics & Characteristics of Included Studies
Study

Type

Lopresti,
Drummond3
(2016)

Randomized
Double
Blind
Placebo
Controlled

Sanmukhani
et al2
(2013)

Lopresti,
Maes et al1
(2014)

Randomized
Controlled
Trial

Randomized
double-blind
placebo
controlled
study

#
Pts
123

45

52

Age
(yrs)
1865

>18

1865

Inclusion
Criteria
Males and
females
meeting the
DSM-IV
criteria for
MDD and had
an IDS-SR30
score greater
than or equal to
18
psychiatry
outpatients of
Sir Takhatsinhji
General
Hospital in
Gujarat India.
Individuals
scored >7 on
Hamilton
Depression
Scale

DSM-IV criteria
for current
major
depressive
disorder and
(IDS-SR30)
score ≥14.

Exclusion Criteria

W/D

Interventions

Psychotic d/o, bipolar,
OCD, PTSD, eating
d/o, substance abuse,
suicidal, diabetes, AI,
CVD, HTN,
neurodegenerative,
fibromyalgia, asthma,
currently pregnant,
breastfeeding,
infection/illness in the
last month, coag d/o

186

High dose and low
dose curcumin (250
mg and 500 mg)

suicidal,
schizophrenic,
schizoaffective, or
other psychotic
disorders, mental
retardation, cognitive
impairment, bipolar
disorder. Abnormal lab
tests, h/o seizure,
thyroid disorder,
allergy, failed at least 2
adequate
antidepressant
therapies or taken any
antidepressant in the
last 30 days, or are
currently receiving
psychotherapy
psychotic d/o, bipolar,
OCD, PTSD, eating
d/o, substance abuse,
high risk of suicide,
diabetics, AI diseases,
CVD, HTN,
neurodegenerative
disorders,
fibromyalgia, asthma,
smokers, pregnant, had
suffered an illness in
past month, any
coagulation disorder

15

and
saffron/curcumin
combination (250
mg of curcumin and
15 mg of saffron)
500 mg curcumin
BID
and
curcumin/fluoxetine
combo
(500 mg curcumin
+ 20 mg fluoxetine)

25

Curcumin 500mg
BID
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OUTCOMES MEASURED
All outcomes measured were POEMs and reflected the efficacy of curcumin on MDD
symptoms. All three RTCs used self-rating tools in which the patients are asked to rate their
depressive symptoms based on the DSM-IV criteria for major depressive episode (inability to
sleep, sexual dysfunction, loss of interest in activities, self-esteem, etc.) In Lopresti, Drummond,
outcomes were measured using IDS-SR30 score and STAI tool.3 In Sanmukhani et al., outcomes
were measured using the HAM-D17 scale, and Lopresti, Maes et al. used IDS-SR30 and STAI
tool.2,1 All RTCs did a baseline analysis using the self-rated tools as well as reanalyzed at various
times throughout the study.

RESULTS
In Lopresti, Maes et al., seventy-seven people were initially screened for the study and
fifty-six met the criteria to join. A placebo and curcumin treatment group were created with
twenty-eight individuals in each. Fifty-two people ultimately completed 8 weeks – 4 dropped
out, one from the placebo and three from the curcumin group. Over the 8 weeks, 500mg
curcumin capsules were given BID to the treatment group, and an identical looking pill
containing cellulose was given to the placebo group. This review will focus on IDS-SR30 score
between weeks 4 and 8. There was a significant change in IDS-SR30 score between weeks 4 and
8 for those receiving the curcumin treatment, p=0.045. Between these weeks, ANOVA F score
was 4.22, which is a large treatment effect due to statistical significance. Additional ANOVA
analyses revealed that IDS-SR30 scores improved in both the placebo and treatment group in the
first 4 weeks, but only continued to improve during the last 4 weeks in the treatment group.
There were no significant changes in STAI scores over the full 8 weeks (baseline-week 4,
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p=0.516; week 4-week 8, p=0.097; baseline-week 8, p=0.358). Adverse events were monitored
and there were no significant differences between the placebo and treatment group, as shown in
Table 2.1

Table 2- List and frequency of adverse events reported by participants. 1
Complaint
No adverse events

Curcumin
16

Placebo
14

Digestive: bloating, nausea,
diarrhea
Respiratory- breathing
problems
Dermatology- dry skin,
flaking skin
Neurology- headaches,
dizziness
Pain- joint pain, back pain,
neck pain
Cardiovascular- racing
heart, chest pain

7

6

0

1

3

2

2

2

2

4

2

0

Vision- sore eyes, dry eyes,
blurry vision

3

0

Auditory- ringing in ears

1

2

Oral- dry mouth, sore gums

2

2

Sanmukhani et al. did a 3-armed study and compared 500 mg BID of curcumin, 20 mg
Fluoxetine, and 20mg Fluoxetine + 500 mg BID curcumin. Sixty patients were split with 20
patients in each group. Forty-five patients completed the full 6 weeks. At the end of the study,
the number of patients who responded to treatment (response is defined as 50% reduction in
HAM-D17 scores compared to baseline) in the fluoxetine + curcumin group was 77.8% compared
to the fluoxetine group of 64.7%.2 Table 3 summarizes these statistics. The numbers needed to
treat (NNT) value is 8, meaning that for every 8 patients with MDD being treated with 20mg of
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fluoxetine + 500 mg BID of curcumin, 1 more patient will have an improvement in their
depressive symptoms compared to fluoxetine alone. This study also evaluated treatment
emergent adverse events (TEAEs) to prove safety of curcumin. The most common adverse event
recorded was gastritis, which was reported in all three groups studied. All TEAEs were mild and
all medications were very well tolerated.2

Table 3- Comparison between combination group and fluoxetine alone.2
Control
event rate
(CER)

Experimental
event rate
(EER)

0.647

0.778

Relative
benefit
increase
(RBI)
0.202

Absolute
benefit
increase
(ABI)
0.131

Number
needed to
treat (NNT)

95% CI; p
value

8

0.58

Lopresti and Drummond did a four-arm study comparing high dose curcumin (500 mg),
low dose curcumin (250 mg), low dose curcumin + saffron, and placebo. 33 patients were placed
in the high dose curcumin, 28 in the low dose curcumin, 26 in low dose curcumin + saffron, and
36 in placebo (n=123). All were placed on placebo for a week prior to being divided into
treatment groups. Ultimately, 49 people were dropped from the study, leaving a total of 111
participants who completing the full 12 weeks. This review will focus on IDS scores. There was
a significant reduction in scores in all groups, except scores only decreased in the first 4 weeks in
the placebo group. When comparing all active treatment groups to placebo, there was a
significant change in IDS score from baseline to 12 weeks, p=0.031.3 Direct comparison of IDS
response rates of high dose curcumin and placebo is seen in Table 4. The NNT value is 7,
meaning that for every 7 patients with MDD being treated with 500 mg curcumin, 1 more patient
will have an improvement in their depressive symptoms compared to placebo. Lopresti and
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Drummond also analyzed adverse events. The high dose curcumin group reported the most
adverse events, although there were of minor severity. The most common complaint was
diarrhea and spicy aftertaste.3

Table 4- Comparison between high dose curcumin and placebo.3
Control
event rate
(CER)

Experiment
event rate
(EER)

Relative
benefit
increase (RBI)

0.13

0.28

1.15

Absolute
benefit
increase
(ABI)
0.15

Number needed
to treat (NNT)

7

DISCUSSION
Two out of the three RCTs incorporated in this paper showed a statistically significant
decrease in depression symptoms in patients suffering from MDD who were treated with
curcumin. Additionally, all three RCTs found that curcumin was a safe intervention with minor
adverse events. Other studies that were done on animal models proved it to be safe even at supratherapeutic doses.2 Curcumin is widely available in the United States and does not require a
prescription. The most common method is one to three capsules of 500 mg.6 It is often used as a
natural supplement for ulcers, analgesic effects, and to relieve flatulence. 6 However, because of
the widespread availability of curcumin, it is difficult to assess the purity and composition of the
capsules being sold. Consequently, the bioavailability of these products is questionable.
Additionally, curcumin is not FDA approved to attest to its efficacy and safety. Therefore,
efficacy and safety is limited to a few clinical trials and it is challenging to determine interaction
with other medications or health conditions. Contraindications to use include allergies,
pregnancy, breast feeding, and those with gallstones or bile duct obstructions. 6
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Weaknesses of all three RCTs were small sample sizes, which limits the reliability of the
findings. Lopresti, Maes et al. and Sanmukhani et al. both had less than 100 participants.
Additionally, Sanmukhani et al. and Lopresti, Drummond had losses to follow-up greater than
20%, meaning that all subjects who entered the trial were not accounted for and attributed at its
conclusion. Sanmukhani et al. also did not use a placebo and also did not have a double-blind
study.
Other limitations of this analysis are the lack of RCTs that evaluate the effects of
curcumin on humans. There are many trials of curcumin results on other animals, such as rats,
but very little on humans. Therefore, the search was limited and only included the three RCTs
that existed and met all inclusion criteria. Two out of the three studies were by the same research
group which limited the diversity and methods used to analyze treatment effect. Lastly, since the
studies only showed significant data after several weeks of treatment, a longer follow up time is
needed to evaluate the full effects of curcumin. Future studies should include a larger patient
population as well as longer follow up time.

CONCLUSIONS
These three chosen studies show that curcumin is a safe and effective treatment option for
patients who suffer from MDD. No serious life-threatening reports were made during the trials
and there is evidence to show that curcumin is safe at supra-therapeutic doses even up to 8
g/day.2
The evaluation of holistic medication on MDD is still underway and the research is still
fairly new. Due to the limited amount of studies and small sample sizes, more studies must be
done to further compare curcumin to other drugs as well as evaluate it over a longer time. Since
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curcumin is a natural spice and not FDA approved, it is imperative to confirm its all-around
safety, especially when taken with other drugs for unrelated diseases. Many patients who suffer
from depression have other coexisting medical diagnoses and may be taking other medications.
In order to fully establish curcumin as safe monotherapy for MDD, future studies should include
drug interactions with other common medications.
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